Arrowhead Pharmaceuticals Inc
ARWRHealthcare|Biotechnology|USA
$59.50
-1.62 (-2.65%)
Tangible Book
$4.09
Graham Number
$11.87
Upcoming Data Readouts (14)
Jun 2026
Est. completion
P3Severe Hypertriglyceridemia
Study of Plozasiran (ARO-APOC3) in Adults With Severe Hypertriglyceridemia
NCT06347003n=446
Jun 2026
Est. completion
P1P2Hyperlipidemia; Mixed
Study of ARO-DIMERPA in Adult Participants With Mixed Hyperlipidemia
NCT07223658n=78
Jun 2026
Est. completion
P3Severe Hypertriglyceridemia
Study of Plozasiran in Adults With Severe Hypertriglyceridemia
NCT06347016n=311
Jul 2026
Est. completion
P1P2Obesity
Study of ARO-ALK7 in Adult Volunteers With Obesity With and Without Type 2 Diabetes Mellitus
NCT06937203n=126
Aug 2026
Est. completion
Dec 2026
Est. completion
P1P2Facio-Scapulo-Humeral Dystrophy
Study of ARO-DUX4 in Adult and Adolescent Patients With Facioscapulohumeral Muscular Dystrophy Type 1
NCT06131983n=60
Dec 2026
Est. completion
Dec 2026
Est. completion
P1Spinocerebellar Ataxia Type 2
Study of ARO-ATXN2 Injection in Adults With Spinocerebellar Ataxia Type 2
NCT06672445n=36
Jun 2027
Est. completion
P1P2Alzheimer Disease
Study of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease
NCT07221344n=112
Jun 2027
Est. completion
Jun 2027
Est. completion
NAOpioid Use Disorder
Adaptive Interventions for Emergency Department Patients With Opioid Use Disorder
NCT06827288n=500
Aug 2027
Est. completion
P3Homozygous Familial Hypercholesterolemia
A Phase 3 Study of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)
NCT07037771n=60
Jul 2028
Est. completion
P3Hypertriglyceridemia
Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia
NCT06822790n=869
Mar 2029
Est. completion
P3Severe Hypertriglyceridemia
Study of Plozasiran in Adults With Severe Hypertriglyceridemia at Risk of Acute Pancreatitis
NCT06880770n=288
Awaiting Results (4)
Trials past primary completion date but still active — data readout may be imminent.
Apr 2024
P3
Study of ARO-APOC3 (Plozasiran) in Adults With Familial Chylomicronemia Syndrome (FCS)
NCT05089084May 2023
P2
Study of ARO-ANG3 in Participants With Homozygous Familial Hypercholesterolemia (HOFH)
NCT05217667